IMI European Lead Factory - democratizing access to high-throughput screening.
Jones PS, Boucharens S, McElroy SP, Morrison A, Honarnejad S, van Boeckel S, van den Hurk H, Basting D, Hüser J, Jaroch S, Ottow E, Benningshof J, Folmer RHA, Leemhuis F, Kramer-Verhulst PM, Nies VJM, Orrling KM, Rijnders T, Pfander C, Engkvist O, Pairaudeau G, Simpson PB, Ortholand JY, Roche D, Dömling A, Kühnert SM, Roevens PWM, van Vlijmen H, van Wanrooij EJA, Verbruggen C, Nussbaumer P, Ovaa H, van der Stelt M, Simonsen KB, Tagmose L, Waldmann H, Duffy J, Finsinger D, Jurzak M, Burgess-Brown NA, Lee WH, Rutjes FPJT, Haag H, Kallus C, Mors H, Dorval T, Lesur B, Ramon Olayo F, Hamza D, Jones G, Pearce C, Piechot A, Tzalis D, Clausen MH, Davis J, Derouane D, Vermeiren C, Kaiser M, Stockman RA, Barrault DV, Pannifer AD, Swedlow JR, Nelson AS, Orru RVA, Ruijter E, van Helden SP, Li VM, Vries T, de Vlieger JSB.
Jones PS, et al. Among authors: van wanrooij eja.
Nat Rev Drug Discov. 2022 Apr;21(4):245-246. doi: 10.1038/d41573-021-00196-3.
Nat Rev Drug Discov. 2022.
PMID: 34907316
No abstract available.
